Innovative Vector Control Consortium (IVCC)

Projet terminé

Vector-borne diseases are a major cause of mortality and morbidity, and hamper economic progress of the poorest. Vector control (VC) is a highly cost-effective measure to address neglected tropical diseases and malaria, but research and development for better VC products remains insufficient. Innovative Vector Control Consortium is the only product development partnership for VC and has a unique position to address this market failure.

Pays/région Thème Période Budget
Monde entier
Santé
Maladies infectieuses
Paludisme
01.08.2018 - 31.07.2020
CHF 3'500'000
Contexte

Vector-borne neglected tropical diseases (NTDs) and malaria are major causes of mortality, morbidity and lack of economic progress for the poorest. Control, elimination and eradication of malaria and insect vector-borne NTDs rely heavily on insecticides, particularly in hyper-endemic areas. Yet VC for prevention of malaria and NTDs is under major threat from insecticide resistance.

Because malaria and NTDs affect the world's poorest people, commercial markets that traditionally drive pharmaceutical company investment in new product research and development (R&D) are lacking. This is where public-private product development partnerships (PDPs) make a difference by being an important global driver for product development.

Product development partnerships like IVCC serve as a platform for R&D of medical products that would otherwise not be developed due to a market failure. The PDPs coordinate the contributions of the private, public, academic and not-for-profit sectors to address the scientific, economic, legal and political challenges that exist in developing new health technologies for the use in developing countries, ensuring their rapid and widespread use. Through the PDPs, the partners in the development of the products, in particular the private sector, typically enter with in-kind contributions and contribute to ensuring access to the developed products at an affordable price.

Switzerland supports four PDPs. IVCC is the only PDP worldwide directed towards the development of VC tools.

Objectifs IVCC’s overarching goal is to reduce transmission of insect-borne pathogens, and ultimately to improve health and reduce poverty resulting from the burden of these infectious diseases, through improved insect VC with new and effective products.
Groupes cibles The burden of NTDs and malaria disproportionally falls on the poorest quartile of the population in disease-endemic countries. IVCC focuses on underpinning prevention as the first and most cost-effective approach to disease control. IVCC targets areas of greatest disease transmission. Hence, it effectively addresses the needs of the poorest quartile of the populations in disease-endemic countries, including above all children under 5 and pregnant women for whom options for treatment are often limited.
Effets à moyen terme

Objective 1: Develop innovative VC tools to prevent insecticide resistance build up and enable malaria elimination.

Objective 2: Implement IVCC’s Access strategy to maximize uptake and impact in resource-poor countries

Objective 3: Keep VC on the technical and political agenda through efficient communication and advocacy

Objective 4: Sustain IVCC’s scientific and technical platforms to provide optimal support to academic and industrial partners

Résultats

Résultats obtenus:  

IVCC was established in 2005 to address the need for innovative VC tools. In collaboration with its partners, IVCC has developed new long lasting insecticide formulations, setting new benchmark for indoor residual spraying (IRS) and bringing insecticides into useable formats for public health.  These products are now in use in the field.

 

IVCC has stimulated the development of an unprecedented pipeline of new and repurposed  insecticide active ingredients as well as new paradigms in VC. Key successes of the first phase include the development of a new long-lasting insecticidal bednet (LLIN) that received recommendation for use by WHO in 2017 as well as a new long-lasting IRS with a novel mode of action chemistry that represents a significant break-through and received WHO prequalification in 2017. Regarding new tools to address insecticide resistance, one particularly promising product has resulted from the first phase that is now being accelerated for development. IVCC’s efforts on advocacy and access resulted in a Declaration of Commitments with major CEOs from the chemical industry in early 2018, an important step to keep key industry actors involved in VC until 2040.

 

The first contribution to IVCC (2014-2017) ended in December 2017. During the second phase, the focus lies on further developing and scaling up the products and to bring them to the market (downstream), thus ensuring access to these products is guaranteed.


Principaux résultats attendus:  

Output 1

 

  • Develop new active ingredients dedicated to public health to support the release of new tools to fight insecticide resistance build up and enable malaria elimination

 

Output 2

 

  • Finalization of global access plans with partners
  • Develop and implement market shaping interventions
  • Develop modelling to anticipate the impact of future products and maximize deployment strategies.

 

Output 3

 

  • Contribute to and influence the global debate on innovative VC and engage in the processes of regulation, policy and advocacy to ensure swift and widespread adoption of best practice and that appropriate financial resources are allocated to facilitate effective innovative VC interventions

 

Output 4

 

  • Sustain IVCC’s scientific and technical platforms to provide optimal support to academic and industrial partners

 

 


Principaux résultats antérieurs:  

IVCC was established in 2005 to address the need for innovative VC tools. In collaboration with its partners, IVCC has developed new long lasting insecticide formulations, setting new benchmark for indoor residual spraying (IRS) and bringing insecticides into useable formats for public health.  These products are now in use in the field. 

IVCC has stimulated the development of an unprecedented pipeline of new and repurposed  insecticide active ingredients as well as new paradigms in VC. Key successes of the first phase include the development of a new long-lasting insecticidal bednet (LLIN) that received recommendation for use by WHO in 2017 as well as a new long-lasting IRS with a novel mode of action chemistry that represents a significant break-through and received WHO prequalification in 2017. Regarding new tools to address insecticide resistance, one particularly promising product has resulted from the first phase that is now being accelerated for development. IVCC’s efforts on advocacy and access resulted in a Declaration of Commitments with major CEOs from the chemical industry in early 2018, an important step to keep key industry actors involved in VC until 2040. 

The first contribution to IVCC (2014-2017) ended in December 2017. During the second phase, the focus lies on further developing and scaling up the products and to bring them to the market (downstream), thus ensuring access to these products is guaranteed


Direction/office fédéral responsable DDC
Crédit Coopération au développement
Partenaire de projet Partenaire contractuel
Institution universitaire et de recherche étrangère
  • Other Academic Research North


Autres partenaires

 

Innovative Vector Control Consortium (IVCC)

Coordination avec d'autres projets et acteurs World Health Organization (WHO); Roll Back Malaria Partnership (RBM), Global Fund to Fight AIDS, TB and Malaria (GFATM), Swiss TPH (i.a. GlobMal, Netcell projects), Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), Foundation for Innovative New Diagnostics (FIND)
Budget Phase en cours Budget de la Suisse CHF   3'500'000 Budget suisse déjà attribué CHF   3'125'752
Phases du projet Phase 3 01.08.2020 - 31.07.2024   (Phase en cours)

Phase 2 01.08.2018 - 31.07.2020   (Completed)

Phase 1 01.01.2014 - 31.12.2017   (Completed)